December 5th 2020
Robert Rifkin, MD, FACP, oncologist and hematologist with Rocky Mountain Cancer Centers and medical director of Biosimilars for McKesson, discusses how his practice is working to correct biosimilar education gaps among physicians and the consequences if those gaps are not addressed.
November 25th 2020
Jorge Garcia, PharmD, MS, MHA, MBA, assistant vice president of the System Oncology Pharmacy Service Line at Baptist Health South Florida, discussed how Baptist Health increases biosimilar use and how innovator companies fight to avoid biosimilar competition.
November 18th 2020
Jorge Garcia, MS, assistant vice president of the System Oncology Pharmacy Service Line at Baptist Health South Florida, discussed how the pandemic has interrupted oncology care for patients and affected the utilization of pegfilgrastim biosimilars.
November 7th 2020
Nabeel Khan, MD, an associate professor of clinical medicine with the University of Pennsylvania, explains how a recent infliximab switching study builds support for use of biosimilars and early treatment with these agents.
November 4th 2020
Nabeel Khan, MD, an associate professor of clinical medicine with the University of Pennsylvania, discussed a study in which patients were switched from reference and biosimilar forms of infliximab to another biosimilar infliximab, Renflexis.
November 1st 2020
Bhuvana Sagar, MD, the national medical executive at Cigna Health Care, discusses the importance of maintaining cost efficiency when juggling multiple biosimilars for 1 originator in the practice setting.
October 29th 2020
Chad Pettit, executive director of marketing and team leader for global biosimilar launches at Amgen, discusses the potential for a level playing field for biosimilars and reference products.
October 27th 2020
Chad Pettit, MBA, executive director of marketing and team leader for global biosimilar launches at Amgen, discussed Amgen’s recent report on the state of the US biosimilars marketplace.
October 20th 2020
Edward Li, PharmD, director of Health Economics and Outcomes Research for Sandoz, discussed how biosimilar filgrastim (Zarxio) used as primary prophylaxis saves money and helps reduce the risk of febrile neutropenia in patients with cancer.
October 15th 2020
Thomas Wakim, strategic analyst for Neuclone, discussed the company’s decision to break into the world of PD-1 inhibitors, its partnership with the Serum Institute in India, and Neuclone’s biosimilar pipeline.
